| Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating ... - WELT ONLINE |
|
|
WELT ONLINEThe incidence of serious adverse events considered drug-related was low, with one event (mild renal impairment) reported in the Viread group and none ... read more |